Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Advenchen Pharmaceuticals LLC maintains a patent portfolio focused on the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action under review. This specific workload is handled by 1 distinct examiner, indicating a narrow point of contact within the patent office compared to portfolios with multiple active matters.
The prosecution activity is confined to 1 distinct art unit. Pierre Paul Eleniste serves as the busiest examiner for the portfolio, responsible for 1 pending office action. This alignment between the total pending actions and the busiest examiner's load shows that the entirety of the company's active prosecution is currently managed by 1 individual.
Practitioners should note that the presence of 1 distinct art unit suggests a specialized technical focus for the pending application. With 1 distinct examiner involved, the company maintains a singular channel of communication. This structure simplifies the administrative burden of managing the current docket. The data indicates a concentrated strategy where all current legal efforts are directed through a centralized point of contact.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ELENISTE, PIERRE PAUL | 1 | 35.5% | +31.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18206506 | BIOLOGICAL ACTIVITIES OF 5-(2-(4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-6-METHOXYQUINOLIN-7-YLOXY)ETHYL)-5-AZASPIRO[2.4]-HEPTAN-7-OL CRYSTALLINE, PHOSPHORIC ACID SALT AND ITS ENANTIOMERS | ELENISTE, PIERRE PAUL | 35d overdue |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18206506 | BIOLOGICAL ACTIVITIES OF 5-(2-(4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-6-METHOXYQUINOLIN-7-YLOXY)ETHYL)-5-AZASPIRO[2.4]-HEPTAN-7-OL CRYSTALLINE, PHOSPHORIC ACID SALT AND ITS ENANTIOMERS | ELENISTE, PIERRE PAUL | 1622 | §112 | Final Rejection | 35d overdue | Pending | Jun 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial